Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
NGM707 is a monoclonal antibody with dual specificity to both ILT2 and ILT4, which inhibits ligand binding including both classical and non-classical MHC-I molecules, potentially resulting in the activation of an immune cell response (Cancer Res 2021;81(13_Suppl):Abstract nr LB156).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|NGM707 + Pembrolizumab||NGM707 Pembrolizumab||0||1|